Triamcinolone Acetonide Extended-Release Injectable Suspension (Zilretta)

Covered: a single FDA‑approved intra‑articular injection of triamcinolone acetonide extended‑release (Zilretta) for osteoarthritis of the knee only; not covered for other joints or if the patient has previously received Zilretta. Key requirements: documentation of knee OA, no prior Zilretta, inadequate response/intolerance/contraindication to at least two of acetaminophen, NSAIDs, or tramadol, and inadequate response to a prior intra‑articular corticosteroid injection, with approval limited to one dose (up to 32 mg) and applicable safety/eligibility documentation.

"Documentation that the patient has NOT previously received Zilretta (prior medication/injection history)."

Sign up to see full coverage criteria, indications, and limitations.